Codexis, Inc.
CDXSHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframeCodexis, Inc. provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United. The $140.2M market capitalization puts CDXS squarely in micro-cap range for its industry. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route.
Market Cap
$140.2M
Beta
2.55
P/E (TTM)
—
P/E (Fwd)
-4.00
EPS (TTM)
$-0.32
EPS (Fwd)
$-0.32
ROE
-69.4%
ROA
-11.7%
Cash
$54.9M
Total Debt
$72.6M
Free CF
$2.1M
52W Change
-52.6%
Annual Financials
Cash vs Debt
Where CDXS stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, CDXS finished 33.67% below its 150-day moving average ($1.99) and 28.26% below its 200-day moving average ($1.84). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CDXS overbought or oversold?
At the October 20, 2026 close, CDXS's RSI(14) was 47.8, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, CDXS has $54.9M in cash with $72.6M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Annual free cash flow of $2.1M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at -69.4%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $138.6M (2022) to $70.4M (2025), a 49% decline worth watching.
A beta of 2.55 means CDXS is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Codexis, Inc. and its sector.